AACR: New CAR T cell therapy benefits patients with advanced...
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting...
AACR: Topical gel relieves painful skin rash side effect...
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality...
AACR: First-in-class covalent Werner helicase inhibitor...
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other...
AACR: Olaparib and pembrolizumab combination shows early promise...
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with...
AACR: Researchers share promising results from MD Anderson...
ABSTRACTS: CT012, CT132, CT265
Researchers from The University of Texas MD Anderson Cancer Center will present promising...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of...
AACR: MD Anderson’s John Weinstein elected Fellow of the...
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
MD Anderson Research Highlights for February 26, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
MD Anderson receives nearly $23 million in CPRIT funding...
The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research...
Scientists find new biomarker that predicts cancer...
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson...